- Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease
- Selected Tau small molecules (Tau Morphomers) have entered into IND/CTA* enabling studies; Phase 1 to commence by the end of 2018
- Increased R&D investment and resources across our key programs
- Financial position remains strong with CHF 109.7 million in cash, allowing the Company to be fully financed through Q2 2019, excluding potential incoming milestones
Find the full media release below.